Compare BRC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | DYN |
|---|---|---|
| Founded | 1914 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 1984 | 2020 |
| Metric | BRC | DYN |
|---|---|---|
| Price | $90.73 | $18.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $39.94 |
| AVG Volume (30 Days) | 176.7K | ★ 2.1M |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 0.61 | N/A |
| EPS | ★ 4.08 | N/A |
| Revenue | ★ $1,541,827,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | ★ 11.21 | N/A |
| 52 Week Low | $62.70 | $6.36 |
| 52 Week High | $88.93 | $25.00 |
| Indicator | BRC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 81.33 | 50.62 |
| Support Level | $83.52 | $17.11 |
| Resistance Level | $86.37 | $19.39 |
| Average True Range (ATR) | 1.53 | 0.95 |
| MACD | 0.47 | 0.20 |
| Stochastic Oscillator | 100.00 | 69.76 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.